000148354 001__ 148354
000148354 005__ 20250116161254.0
000148354 0247_ $$2doi$$a10.1136/thoraxjnl-2019-213622
000148354 0248_ $$2sideral$$a117596
000148354 037__ $$aART-2020-117596
000148354 041__ $$aeng
000148354 100__ $$aMasa, J.F.
000148354 245__ $$aCost-effectiveness of positive airway pressure modalities in obesity hypoventilation syndrome with severe obstructive sleep apnoea
000148354 260__ $$c2020
000148354 5203_ $$aBackground: Obesity hypoventilation syndrome (OHS) is treated with either non-invasive ventilation (NIV) or CPAP, but there are no long-term cost-effectiveness studies comparing the two treatment modalities.
Objectives: We performed a large, multicentre, randomised, open-label controlled study to determine the comparative long-term cost and effectiveness of NIV versus CPAP in patients with OHS with severe obstructive sleep apnoea (OSA) using hospitalisation days as the primary outcome measure.
Methods: Hospital resource utilisation and within trial costs were evaluated against the difference in effectiveness based on the primary outcome (hospitalisation days/year, transformed and non-transformed in monetary term). Costs and effectiveness were estimated from a log-normal distribution using a Bayesian approach. A secondary analysis by adherence subgroups was performed.
Results: In total, 363 patients were selected, 215 were randomised and 202 were available for the analysis. The median (IQR) follow-up was 3.01 (2.91-3.14) years for NIV group and 3.00 (2.92-3.17) years for CPAP. The mean (SD) Bayesian estimated hospital days was 2.13 (0.73) for CPAP and 1.89 (0.78) for NIV. The mean (SD) Bayesian estimated cost per patient/year in the NIV arm, excluding hospitalisation costs, was 2075.98 (91.6), which was higher than the cost in the CPAP arm of 1219.06 (52.3); mean difference 857.6 (105.5). CPAP was more cost-effective than NIV (99.5% probability) because longer hospital stay in the CPAP arm was compensated for by its lower costs. Similar findings were observed in the high and low adherence subgroups.
Conclusion: CPAP is more cost-effective than NIV; therefore, CPAP should be the preferred treatment for patients with OHS with severe OSA. Trial registration number: NCT01405976
000148354 540__ $$9info:eu-repo/semantics/closedAccess$$aAll rights reserved$$uhttp://www.europeana.eu/rights/rr-f/
000148354 590__ $$a9.139$$b2020
000148354 591__ $$aRESPIRATORY SYSTEM$$b7 / 64 = 0.109$$c2020$$dQ1$$eT1
000148354 592__ $$a3.083$$b2020
000148354 593__ $$aPulmonary and Respiratory Medicine$$c2020$$dQ1
000148354 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000148354 700__ $$aMokhlesi, B.
000148354 700__ $$aBenítez, I.
000148354 700__ $$aGómez De Terreros Caro, F.J.
000148354 700__ $$aSánchez-Quiroga, M.A.
000148354 700__ $$aRomero, A.
000148354 700__ $$aCaballero, C.
000148354 700__ $$aAlonso-Álvarez, M.L.
000148354 700__ $$aOrdax-Carbajo, E.
000148354 700__ $$aGómez-Garciá, T.
000148354 700__ $$aGonzález, M.
000148354 700__ $$aLópez-Martín, S.
000148354 700__ $$0(orcid)0000-0001-9096-2294$$aMarin, J.M.$$uUniversidad de Zaragoza
000148354 700__ $$aMartí, S.
000148354 700__ $$aDiáz-Cambriles, T.
000148354 700__ $$aChiner, E.
000148354 700__ $$aEgea, C.
000148354 700__ $$aBarca, J.
000148354 700__ $$aVázquez-Polo, F.J.
000148354 700__ $$aNegrín, M.A.
000148354 700__ $$aMartel-Escobar, M.
000148354 700__ $$aBarbé, F.
000148354 700__ $$aCorral-Penãfiel, J.
000148354 7102_ $$11007$$2610$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Medicina
000148354 773__ $$g75, 6 (2020), NCT01405976 [9 pp]$$pThorax$$tThorax$$x0040-6376
000148354 8564_ $$s1525586$$uhttps://zaguan.unizar.es/record/148354/files/texto_completo.pdf$$yVersión publicada
000148354 8564_ $$s2969160$$uhttps://zaguan.unizar.es/record/148354/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000148354 909CO $$ooai:zaguan.unizar.es:148354$$particulos$$pdriver
000148354 951__ $$a2025-01-16-14:31:50
000148354 980__ $$aARTICLE